ReviewFrontiers in artificial intelligence2025
Artificial intelligence in ADHD assessment: a comprehensive review of research progress from early screening to precise differential diagnosis.
Review in Frontiers in artificial intelligence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Wearable-Derived Axis-Specific Motor Signatures of ADHD Symptoms in Children and Adolescents.Biosensors · 2026Article
- Hypothalamic-pituitary-adrenal axis activity and neurotrophic factors in drug-naive children and adolescents with attention-deficit/hyperactivity disorder.Frontiers in psychiatry · 2026Article
- Early diagnosis and developmental outcome prediction of agenesis of the corpus callosum via an interpretable deep multimodal fusion model.Frontiers in neuroscience · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention deficit hyperactivity disorder (ADHD) diagnosis traditionally relies on subjective assessments, which lead to challenges like symptom overlap, heterogeneity, and misdiagnosis risk. Artificial intelligence (AI), especially machine learning (ML) and deep learning (DL), offers objective assessment opportunities by processing complex multimodal data (behavioral, neurophysiological, neuroimaging, genetic). This paper reviews AI's current applications in objective ADHD assessment, covering early screening, risk prediction, diagnostic assistance, classification, assistance in precise differential diagnosis, symptom quantification, and heterogeneous subtype identification. While AI models show significant potential in extracting objective biomarkers and improving assessment efficiency, the field faces challenges: insufficient standardized data, limited generalization, interpretability issues, potential biases, and lack of rigorous clinical validation. Future research must establish large-scale, standardized multimodal databases, develop robust, interpretable, and fair AI models, and conduct rigorous clinical translation validation to achieve responsible, precise, objective, and personalized ADHD assessment and management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.